I think you're misunderstanding the difference between
I think you're misunderstanding the difference between share price and market cap. If Cytodyn today were to do a reverse split of say 100 to 1, our share price would be around $20 but our value would not change. That would not make another company more likely to buy us for more money, they're going to spend the same $20 billion (or whatever number they pick) regardless of share price.
If we have stellar results in our phase 2 mssCRC trial and our market cap rises because we look closer to approval, our share price will go up and a company would purchase us for more because the risk to them would decrease.
My point in bringing up share value not really mattering to a purchasing company is because several people have said "Company X got bought out for $80/share" and think that means we should be bought out around that amount. But if they only had 40 million shares outstanding, that's only $3.2 billion dollars which would only equate to ~$2.13 a share for Cytodyn to reach the same $3.2 billion value.
Of course, you are correct that how much someone will pay vs. how much someone will accept plays into the actual purchase price of the company, that's how negotiations work. We also likely wouldn't see the company bought out for large multiples of our current value but that's because we're more likely to see a partnership where we have to prove the drug out in trials before they will consider a BO so our value will rise as we achieve milestones that make us more attractive for a BO. Believe it or not we're still considered a risky investment to BP even though everyone on this board knows that it's when, not if. The less risky we become, the bigger that buyout number becomes.
7
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...
Continue Reading
Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...
Continue Reading
A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...
Continue Reading
Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...
Continue Reading
Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...
Continue Reading
Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...
Continue Reading
A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...
Continue Reading
Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...
Continue Reading
Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...
Continue Reading
Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...
Continue Reading
Top 5 Most Recently Viewed Articles
Luca Mining Corp. Strengthens Leadership Team Luca Mining Corp. (TSXV: LUCA) (OTCQX: LUCMF) is thrilled to announce a strategic addition to its team with the appointment of Mr. Adam Melnyk as Vice President of Corporate Development. This move is set to elevate the company’s business development initiatives and drive growth as it aims to expand its operations in the...
Continue Reading
Sapiens Hosts Global Client Conference to Transform Insurance This event unites insurance leaders to exchange ideas for growth, adaptability, and impactful business strategies. Sapiens International Corporation (NASDAQ: SPNS) recently held its annual International Client Conference, gathering insurance professionals, prospects, and partners for three days of insightful...
Continue Reading
Elon Musk's Transformation into a Political Influencer Elon Musk, renowned for his groundbreaking ventures, has recently emerged as a key advocate for former President Donald Trump. Through his platform X, formerly known as Twitter, Musk is significantly amplifying conservative viewpoints. A Shift in Political Engagement Musk’s political activity has noticed a marked...
Continue Reading
Enphase Energy's Earnings Anticipation Enphase Energy Inc. (NASDAQ: ENPH) is preparing to announce its third-quarter earnings. The anticipated earnings per share stand at 77 cents, with expected revenue reaching approximately $391.98 million. Despite these expectations, investor sentiment appears to be less than optimistic. This solar energy company has faced significant...
Continue Reading
Market Update: Examining Leadership Shifts As global yields rise, US megacaps face pressure as investors revisit the 'Sell America' strategy. Notably, the S&P 500 has recently broken important technical levels, with noticeable fatigue in tech, media, and telecom leadership. On the other hand, diversification appears to be paying off, as small caps, foreign equities, and...
Continue Reading